Topic Hub
32 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 32 of 32 clinical reviews.
A clinical and insurance guide explaining Aetna's current coverage position on epitalon, prior-authorization steps, appeal pathways, and cash-pay alternatives for patients seeking this tetrapeptide.
Read clinical reviewEpitalon tetrapeptide has no FDA approval or established adolescent dosing. This evidence review covers the limited research, safety concerns for ages 12 to 17, and why off-label pediatric use carries significant risk.
Read clinical reviewA clinician-focused guide to monitoring epitalon tetrapeptide use in adolescents aged 12, 17, covering safety signals, growth-velocity tracking, endocrine effects, and evidence gaps.
Read clinical reviewEvidence-based guide to epitalon tetrapeptide dosing for adults aged 30 to 49, covering subcutaneous injection protocols, cycle structure, monitoring, and safety data from published research.
Read clinical reviewA clinical comparison of epitalon tetrapeptide pricing against TA-65, GHK-Cu, NAD+ precursors, and other longevity-class compounds, with mechanism breakdowns and evidence grading.
Read clinical reviewEvidence-based review of epitalon tetrapeptide drug-drug interactions, covering telomerase activation, CYP metabolism, peptide clearance pathways, and co-administration risks with common medications.
Read clinical reviewEvidence-based guide to epitalon tetrapeptide dosing in adults aged 65 and older, covering cycle length, renal adjustments, drug interactions, and monitoring.
Read clinical reviewA clinical review of epitalon tetrapeptide safety in adults aged 65 and older, covering telomerase data, renal considerations, drug interactions, and geriatric-specific risks.
Read clinical reviewA physician-level review of epitalon's origins in Soviet bioregulation research, its synthesis by Vladimir Khavinson, telomerase activation data, and current regulatory status.
Read clinical reviewA clinical review of epitalon tetrapeptide research in special populations including organ transplant recipients, people living with HIV, and other immunocompromised groups. Covers telomerase activation data, safety unknowns, and why no guideline endorses off-label use.
Read clinical reviewA clinical review of epitalon tetrapeptide manufacturing processes, global supply chain dynamics, shortage events, and quality control challenges for this research-grade longevity peptide.
Read clinical reviewA physician-level deep dive into how the tetrapeptide Epitalon (Ala-Glu-Asp-Gly) activates telomerase, modulates melatonin synthesis, and influences cellular aging pathways, with PubMed-cited evidence.
Read clinical reviewEvidence-based guidance on handling missed epitalon tetrapeptide doses during a 10-20 day cycle, including timing adjustments, telomerase considerations, and when to restart.
Read clinical reviewEvidence-based monitoring guide for epitalon tetrapeptide in adults aged 30-49, covering baseline blood work, telomere testing, hormonal panels, melatonin markers, and cycle-specific safety checks.
Read clinical reviewA physician-reviewed monitoring schedule for epitalon tetrapeptide, covering baseline labs, mid-cycle checkpoints, and post-cycle follow-up with specific biomarkers and timing.
Read clinical reviewA clinical review of epitalon tetrapeptide off-label applications, from telomerase activation and melatonin regulation to immune modulation and antitumor research, with graded evidence levels and primary-source citations.
Read clinical reviewA clinical review of epitalon tetrapeptide patent status, intellectual property history, regulatory pathway, and what the absence of FDA approval means for generic availability and patient access.
Read clinical reviewA comprehensive clinical review of epitalon tetrapeptide dosing in children under 12, covering the absence of approved pediatric dosing, available research evidence, safety considerations, and why no responsible clinician should prescribe this peptide to young children without far more data.
Read clinical reviewA clinical reference on epitalon tetrapeptide use in children under 12, covering safety signals, monitoring parameters, dosing considerations, and the current evidence base for pediatric oversight.
Read clinical reviewEpitalon has zero published pediatric safety data in children under 12. This article reviews the preclinical evidence, regulatory status, telomerase biology in developing children, and why no responsible clinician should prescribe this peptide to a child.
Read clinical reviewHow genetic differences in telomerase, clock genes, and peptide metabolism shape individual responses to epitalon tetrapeptide therapy.
Read clinical reviewA clinician-grade review of epitalon tetrapeptide pharmacokinetics covering absorption after subcutaneous injection, tissue distribution, peptidase-driven metabolism, and renal elimination, with cited primary sources.
Read clinical reviewIs epitalon safe during pregnancy or breastfeeding? A clinical review of the tetrapeptide's reproductive safety data, telomerase effects on fetal development, and current medical guidance.
Read clinical reviewA clinical review of epitalon tetrapeptide real-world evidence, including registry data, observational cohorts, and the gap between preclinical telomerase activation and human outcomes.
Read clinical reviewA clinical review of epitalon tetrapeptide's regulatory classification in the United States, European Union, Canada, and United Kingdom, including legal purchase pathways and research-use distinctions.
Read clinical reviewA clinical review of epitalon tetrapeptide safety data for adults aged 30 to 49, covering telomerase activation, side effects, dosing protocols, drug interactions, and regulatory status.
Read clinical reviewA clinician-reviewed safety guide for epitalon tetrapeptide use in adults aged 50 to 64, covering current evidence, contraindications, drug interactions, and monitoring recommendations.
Read clinical reviewA clinical review of epitalon tetrapeptide safety in adults aged 18, 29, covering telomere biology, known risks, dosing considerations, fertility implications, and what current evidence does and does not support.
Read clinical reviewA physician-reviewed analysis of epitalon tetrapeptide safety in adolescents aged 12 to 17, covering telomerase biology, growth-axis risks, regulatory status, and the near-total absence of pediatric trial data.
Read clinical reviewEvidence-based guide to epitalon tetrapeptide dosing for young adults aged 18-29, covering cycle length, subcutaneous injection protocols, telomerase research, and safety considerations.
Read clinical reviewA complete clinical monitoring guide for adults aged 18-29 using epitalon tetrapeptide, covering baseline labs, cycle tracking, fertility considerations, and safety checkpoints backed by primary research.
Read clinical reviewEvidence-based discontinuation protocol for epitalon tetrapeptide, including tapering guidance, post-cycle monitoring, and telomerase activity considerations.
Read clinical review